Business Context and Reporting Period
Company: SAB Biotherapeutics, Inc. (SABS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: SAB is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders. The company utilizes a proprietary platform involving transchromosomic cattle (Tc-Bovine) to produce human antibodies without human plasma donors. The lead product candidate, SAB-142, is a human anti-thymocyte globulin (hATG) in development for Type 1 Diabetes (T1D).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $1.32 million (Government grants) |
| Net Income (Loss) | $13.27 million | $(34.11) million |
| Operating Loss | $(48.95) million | $(42.91) million |
| Research & Development Expenses | $34.35 million | $30.25 million |
| General & Administrative Expenses | $14.60 million | $13.98 million |
| Cash, Cash Equivalents & Investments | $143.5 million | $20.8 million |
| Warrant Liability Fair Value | $5.64 million | $6.39 million |
Note: The 2025 Net Income is primarily driven by a non-cash gain of $62.75 million related to the change in fair value of warrant liabilities, specifically the reclassification of Series B warrants from liability to equity following shareholder approval.
Material Changes vs. Prior Period
- Revenue: Decreased 100% to $0 in 2025 due to the termination of government grants (JPEO Rapid Response Contract) that generated $1.32 million in 2024.
- Operating Expenses: Total operating expenses increased by $4.72 million (10.7%) to $48.95 million.
- R&D: Increased by $4.1 million (13.6%), driven by a $6.0 million increase in clinical trial expenses (initiation of Phase 2b SAFEGUARD study) and a $4.8 million increase in salaries and benefits.
- G&A: Increased by $0.62 million (4.4%), primarily due to higher administrative support fees.
- Liquidity: Cash and investments increased significantly from $20.8 million to $143.5 million, primarily due to a Series B private placement offering in July 2025 that generated approximately $175 million in gross proceeds.
- Non-Operating Income: Increased by $53.2 million, driven almost entirely by the $57.4 million gain on the change in fair value of warrant liabilities.
Guidance, Outlook, and Risks
Clinical Progress & Outlook
- SAB-142 Phase 1: Positive topline data announced in January and December 2025. The trial demonstrated a favorable safety profile with 0% serum sickness and 0% neutralizing anti-drug antibodies (ADAs), contrasting with historical rabbit ATG data.
- SAB-142 Phase 2b (SAFEGUARD): Initiated in Q3 2025 with the first patient dosed in December 2025. This global, registrational trial targets 159 patients with new-onset Stage 3 T1D. Topline data is expected in the second half of 2027.
- Regulatory: The company confirmed intent with the FDA to utilize SAFEGUARD data as primary evidence for future regulatory approval.
Management Commentary
Management expects to continue generating operating losses as they advance SAB-142 through Phase 2 trials and invest in commercialization infrastructure. Based on current operating expenses and the capital raised in 2025, the company states it has sufficient resources to cover operating cash needs for at least the next twelve months.
Risks and Contingencies
- Clinical Failure: As a clinical-stage company, there is no assurance that SAB-142 will demonstrate efficacy in the Phase 2b trial or receive regulatory approval.
- Manufacturing: The company relies on a proprietary platform using genetically engineered cattle. Risks include disease outbreaks in the herd, scaling difficulties, and regulatory hurdles regarding the New Animal Drug Application (NADA).
- Capital Requirements: While liquidity improved in 2025, the company will require additional capital in the future to fund operations and commercialization. Failure to raise capital could force scaling back of operations.
- Government Shutdowns: The filing notes a 43-day federal government shutdown in late 2025 and partial shutdowns in early 2026, which could delay regulatory reviews and funding.
Key Facts for Investor Verification
- Cash Runway: Verify the company's assertion that current resources ($143.5M) are sufficient for at least 12 months given the high burn rate associated with the Phase 2b trial.
- SAFEGUARD Trial Enrollment: Monitor the pace of patient enrollment in the Phase 2b SAFEGUARD study, as delays could push back the expected 2027 data readout.
- Warrant Liability Accounting: Understand that the 2025 net income is non-operational and driven by accounting adjustments to warrant liabilities, not product sales or operational efficiency.
- Manufacturing Scalability: Assess the progress of scaling the Tc-Bovine production platform to meet potential commercial demand, including the status of the second redundant animal facility.
- Regulatory Pathway: Confirm the FDA's continued alignment with the plan to use the Phase 2b study as the primary basis for a Biologics License Application (BLA).